Primary and secondary autoimmune neutropenia

Area of Science:

• Immunology
• Hematology
• Clinical Medicine

Background:

• Antineutrophil antibodies are a known cause of neutropenia, leading to neutrophil dysfunction and heightened infection susceptibility.
• Autoimmune neutropenia (AIN) presents in infancy as a self-limiting condition with mild infections, while chronic idiopathic neutropenia affects older individuals, predominantly females, with rare remissions.
• Secondary AIN in adults is linked to various conditions like collagen disorders, viral infections, and lymphoproliferative diseases.

Purpose of the Study:

• To review the causes, characteristics, and treatment of autoimmune neutropenia.
• To highlight the role of antineutrophil antibodies in neutropenia.
• To discuss current therapeutic strategies for AIN.

Main Methods:

• Literature review of studies on antineutrophil antibodies and neutropenia.
• Analysis of clinical presentations and outcomes in different AIN subtypes.
• Evaluation of treatment efficacy, focusing on granulocyte colony-stimulating factor.

Main Results:

• Antibodies in AIN typically target IgG Fc receptor type 3b, with other antigens identified in secondary AIN.
• Primary AIN of infancy is generally mild and self-limiting.
• Chronic idiopathic neutropenia and secondary AIN have distinct epidemiological and etiological profiles.

Conclusions:

• Granulocyte colony-stimulating factor (G-CSF) is an effective and preferred treatment for all forms of autoimmune neutropenia.
• Understanding the diverse causes and presentations of AIN is crucial for appropriate management.
• Further research into novel target antigens may refine diagnostic and therapeutic approaches for secondary AIN.